Search results
Added:
3 years ago
The therapy of patients with chronic heart failure (HF) due to systolic left ventricular dysfunction (SLVD) continues to evolve. There is agreement that all patients with HF due to SLVD should be treated with an angiotensin converting enzyme inhibitor (ACE-I) and a beta-adrenergic receptor blocking agent (BB) unless contraindicated or not tolerated. The role of angiotensin receptor blocking…
View more
Added:
3 years ago
Mitral regurgitation (MR) is common in industrialized countries, with a prevalence of about 2% in the general population and about 9% in people over 75 years old.1,2 MR is classified as primary/degenerative when it results from a structural abnormality of the valve apparatus, or secondary/functional when it results from a disturbance of ventricular or annular geometry and/or function that impairs…
View more
Added:
3 years ago
Volume Overload in Heart Failure
The burden of heart failure (HF) remains formidable in the US, with nearly one million annual hospital admissions and frequent outpatient visits to a variety of care providers.1 While HF outcomes have improved modestly over the past several decades, many patients still struggle to maintain a satisfactory quality of life.2 Implantable cardioverter–defibrillators…
View more
Added:
4 months ago
Added:
1 year ago
HFSA 22 - Dr James Januzzi (Massachusetts General Hospital, US) outlines the findings of the PROVE-HF study, a trial which aimed to determine the effect of sacubitril/valsartan therapy on cardiac biomarkers in patients with mitral regurgitation in heart failure with reduced ejection fraction.
Questions:
1. What was the ideology behind PROVE-HF?
2. What is the mechanism of action behind…
View more
Added:
3 years ago
A growing appreciation of the prevalence of sleep breathing disorders, especially as comorbidities of disease syndromes such as chronic heart failure, has increased interest in screening, diagnosis, and treatment of obstructive and central sleep apnea. Sleep apnea diagnosis currently requires an overnight polysomnograhic evaluation in which the disease is defined as the number of times per hour…
View more
The PRESERVED-HF Study
Added:
2 years ago
Video
Added:
3 years ago
In the wake of transcatheter aortic valve replacement revolutionizing the treatment of aortic stenosis, sizeable interest has arisen in the development of percutaneous technologies to treat patients with mitral valve disease. Thus, when a percutaneous method of edge-to-edge mitral valve repair (TMVr) using the MitraClip device (Abbott Vascular) was introduced, this device was met with…
View more
Added:
7 months ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID study (NCT03037931).
HEART-FID(American Regent, Inc.) aimed to determine the safety and efficacy of iron therapy using intravenous (IV) ferric carboxymaltose (FCM) as compared to a placebo in the treatment of patients with heart…
View more
Shelley Zieroth
Research Area(s) / Expertise:
Job title: Director, Heart Failure and Heart Transplant Clinics
Author
« First